GSK plc (GSK) NYSE

49.00

-0.31(-0.63%)

Updated at June 02 04:00PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Luke V. Miels	Chief Executive Officer & Director	6.07M	1974
Jesse L. Goodman	Scientific & Medical Expert	83,000	1951
Julie Brown	Chief Financial Officer & Executive Director	6.04M	1962
Emma Natasha Walmsley	Executive Officer	7.58M	1969
Roanne Parry	Chief People Officer	0	1974
David Simon Redfern	President of Corporate Development	0	1966
James Ford	Senior Vice President & Group General Counsel of Legal & Compliance	0	N/A
Philip C. Thomson	President of Global Affairs	0	N/A
Tony Wood	Chief Scientific Officer and Head of R&D	0	N/A
Constantin Fest	Senior Vice President & Head of Investor Relations	0	1977
Diana Conrad	Chief People Officer	0	N/A
Shobie Ramakrishnan	Chief Digital & Technology Officer	0	1971

Name

Title

Pay

Year Born

Luke V. Miels

Chief Executive Officer & Director

6.07M

1974

Jesse L. Goodman

Scientific & Medical Expert

83,000

1951

Julie Brown

Chief Financial Officer & Executive Director

6.04M

1962

Emma Natasha Walmsley

Executive Officer

7.58M

1969

Roanne Parry

Chief People Officer

1974

David Simon Redfern

President of Corporate Development

1966

James Ford

Senior Vice President & Group General Counsel of Legal & Compliance

N/A

Philip C. Thomson

President of Global Affairs

N/A

Tony Wood

Chief Scientific Officer and Head of R&D

N/A

Constantin Fest

Senior Vice President & Head of Investor Relations

1977

Diana Conrad

Chief People Officer

N/A

Shobie Ramakrishnan

Chief Digital & Technology Officer

1971

Description

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.